|
Volumn 23, Issue 15, 2015, Pages 4364-4374
|
Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors
|
Author keywords
Anti proliferative; HDAC; Hydroxamic acid; Inhibitor; Quinoline
|
Indexed keywords
HISTONE DEACETYLASE;
HISTONE DEACETYLASE INHIBITOR;
HYDROXAMIC ACID DERIVATIVE;
N1 HYDROXY N5 (QUINOLIN 2 YLMETHYL)GLUTARAMIDE;
N1 HYDROXY N6 (QUINOLIN 2 YLMETHYL)ADIPAMIDE;
N1 HYDROXY N7 (QUINOLIN 2 YLMETHYL)HEPTANEDIAMIDE;
N1 HYDROXY N7 [[4 (METHYLCARBAMOYL)QUINOLIN 2 YL]METHYL]HEPTANEDIAMIDE;
N1 HYDROXY N7 [[4 (PHENYLCARBAMOYL)QUINOLIN 2 YL]METHYL]HEPTANEDIAMIDE;
N1 HYDROXY N8 (QUINOLIN 2 YLMETHYL)OCTANEDIAMIDE;
N1 HYDROXY N8 [[4 (METHYLCARBAMOYL)QUINOLIN 2 YL]METHYL]OCTANEDIAMIDE;
N1 HYDROXY N8 [[4 (PHENYLCARBAMOYL)QUINOLIN 2 YL]METHYL]OCTANEDIAMIDE;
N1 [(6 BROMOQUINOLIN 2 YL)METHYL] N7 HYDROXYHEPTANE DIAMIDE;
N1 [(6 BROMOQUINOLIN 2 YL)METHYL] N8 HYDROXYOCTANE DIAMIDE;
N1 [(6 CHLOROQUINOLIN 2 YL)METHYL] N7 HYDROXYHEPTANE DIAMIDE;
N1 [(6 FLUOROQUINOLIN 2 YL)METHYL] N7 HYDROXYHEPTANE DIAMIDE;
N1 [[4 (BENZYLCARBAMOYL) 6 BROMOQUINOLIN 2 YL]METHYL] N7 HYDROXYHEPTANEDIAMIDE;
N1 [[4 (BENZYLCARBAMOYL) 6 BROMOQUINOLIN 2 YL]METHYL] N8 HYDROXYOCTANEDIAMIDE;
N1 [[4 (BENZYLCARBAMOYL) 6 BROMOQUINOLIN 2 YL]METHYL] N9 HYDROXYNONANEDIAMIDE;
N1 [[4 (BENZYLCARBAMOYL)QUINOLIN 2 YL]METHYL] N5 HYDROXYGLUTARAMIDE;
N1 [[4 (BENZYLCARBAMOYL)QUINOLIN 2 YL]METHYL] N6 HYDROXYADIPAMIDE;
N1 [[4 (BENZYLCARBAMOYL)QUINOLIN 2 YL]METHYL] N7 HYDROXYHEPTANEDIAMIDE;
N1 [[4 (BENZYLCARBAMOYL)QUINOLIN 2 YL]METHYL] N8 HYDROXYOCTANEDIAMIDE;
N1 [[4 (BENZYLCARBAMOYL)QUINOLIN 2 YL]METHYL] N9 HYDROXYNONANEDIAMIDE;
N1 [[4 (BUTYLCARBAMOYL)QUINOLIN 2 YL]METHYL] N7 HYDROXYHEPTANEDIAMIDE;
N1 [[4 (BUTYLCARBAMOYL)QUINOLIN 2 YL]METHYL] N8 HYDROXYOCTANEDIAMIDE;
N1 [[6 BROMO 4 (PHENYLCARBAMOYL)QUINOLIN 2 YL]METHYL] N7 HYDROXYHEPTANEDIAMIDE;
N1 [[6 BROMO 4 (PHENYLCARBAMOYL)QUINOLIN 2 YL]METHYL] N8 HYDROXYOCTANEDIAMIDE;
QUINOLINE DERIVATIVE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VORINOSTAT;
HYDROXAMIC ACID;
QUINOLINE;
ANTINEOPLASTIC ACTIVITY;
ANTIPROLIFERATIVE ACTIVITY;
ARTICLE;
CONTROLLED STUDY;
DRUG DESIGN;
DRUG IDENTIFICATION;
DRUG STRUCTURE;
DRUG SYNTHESIS;
ENZYME INHIBITION;
HUMAN;
HUMAN CELL;
IC50;
IN VITRO STUDY;
TUMOR CELL LINE;
BINDING SITE;
CELL SURVIVAL;
CHEMISTRY;
DRUG EFFECTS;
DRUG SCREENING;
METABOLISM;
MOLECULAR DOCKING;
PROTEIN TERTIARY STRUCTURE;
STRUCTURE ACTIVITY RELATION;
SYNTHESIS;
BINDING SITES;
CELL LINE, TUMOR;
CELL SURVIVAL;
DRUG DESIGN;
DRUG SCREENING ASSAYS, ANTITUMOR;
HISTONE DEACETYLASE INHIBITORS;
HISTONE DEACETYLASES;
HUMANS;
HYDROXAMIC ACIDS;
MOLECULAR DOCKING SIMULATION;
PROTEIN STRUCTURE, TERTIARY;
QUINOLINES;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 84937973886
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2015.06.024 Document Type: Article |
Times cited : (41)
|
References (19)
|